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potentially denying patients access to surgery that was feasible. The
prognosis for unoperated severe symptomatic AS was very poor,
reinforcing the role of intervention. Although testing is still
preliminary, less invasive delivery of devices for the treatment of
severe AS may find a role in patients with truly prohibitive
operative risk.
It could be attractive to assume that these data are unique to
a single institution. However, the surveyed institution has an
active program in the treatment of valvular heart disease. The
authors believe that these findings are likely reflective of general
practice.
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Letters to the Editor
Myocardial Late Enhancement in
Duchenne and Becker Individuals
in the Clinical Milieu
We read with interest the study by Silva et al. (1) of myocardial
delayed enhancement (MDE) in patients with muscular dystrophy.
This study focuses on 10 patients, 8 Duchenne muscular dystrophy
(DMD) and 2 Becker muscular dystrophy (BMD) individuals age
7 to 18 years, 2 having dilated cardiomyopathy (DCM). It raises
several issues.
The authors reported a significant correlation between MDE, as
a marker of myocardial fibrosis (MF), and low left ventricular
ejection fraction (EF) values.
Although only 2 patients had MF and abnormal echocardiog-
raphy, their EF values were not shown. Similarly, the correlation
between EF and MF in the 5 patients with MF and normal
echocardiography should be focused on, as a wide variability in EF
data (37.3% to 59.3%) was observed.
Correlation between contractile dysfunction and MF seems
ambiguous, as 56.2% of dysfunctional segments had MF, whereas
43.8% did not.
Lack of muscle biopsy renders the diagnosis of 4 patients
incomplete: Patients #2 and #3 diagnosed as DMD, carrying an
in-frame (Becker) deletion. Patients #5 and #6 (siblings) were
diagnosed as BMD, despite the absence of muscle biopsy data. In
these patients without cardiomyopathy, the differential diagnosis
with limb-girdle dystrophy should be considered.
Seven patients had no deletions of the dystrophin gene. Sur-
prisingly, in these patients, screening for duplications or splicing
mutations was not performed. Indeed, Patients #1, #5, and #10
(without MF) could have early cardiac involvement undetectable
by cardiac magnetic resonance and develop severe DCM (2).
Finally, even the youngest patients (Patients #7 and #8) with MF
had no screening for mutations.
Regarding the early detection of heart involvement by cardiac
magnetic resonance in children, the authors did not cite ultrasound
tissue characterization analysis (3) that reveals early occult cardiac
involvement in all affected individuals.
Figure 1 Survival of Patients With Unoperated AS
Kaplan-Meier survival for patients with unoperated severe aortic stenosis (AS).
Survival estimates  1 standard error; log-rank difference in survival p  0.01.
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The authors should be highly critical in their assumptions,
emphasizing the uncertainties of the conclusions, specifically in
view of the small study group.
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Reply
We appreciate the letter written in response to our recent article
(1). We address the questions of Dr. Giglio and colleagues in the
following text.
We demonstrated a clear correlation between amount of myo-
cardial delayed enhancement and lower left ventricular ejection
fraction (LVEF). Although only Patients #3 and #9 had low LVEF
(47% and 42%) by echocardiography, they had even lower LVEF by
CMR (36.7% and 33.6%). Additionally, cardiovascular magnetic
resonance (CMR) detected 6 patients with mild to moderate LV
dysfunction (4 patients) or low-normal LVEF (2 patients).
We disagree that the focus should be on the wide variability of
ejection fraction. Despite the variability (small n), we noted a large
and significant difference in LVEF by CMR in patients with
versus without MF (48.3  11.0% vs. 66.1  0.6%, p  0.02),
whereas no difference was observed by echocardiography (52.4 
8.4% vs. 59.6  5.5%, p  NS). Thus, CMR detected subtle LV
function changes in patients with myocardial fibrosis (MF). Even
in the range of normal to mild dysfunction, the correlation held
true: the higher the amount of MF, the lower the LVEF.
We disagree that contractile dysfunction and MF seem ambig-
uous. Dysfunctional segments can influence adjacent segment
contraction, even those without MF, by a complex relationship
that depends critically on the amount of segmental MF, global LV
function, and remodeling (2,3).
Lack of muscle biopsy did not turn the final diagnosis incom-
plete. Patients #2 and #3 have a typical clinical course of Duchenne
muscular dystrophy, becoming wheelchair bound before 10 years
old. Patients #5 and #6 were siblings and have a positive familial
history of X-linked inheritance, excluding limb-girdle dystrophy
hypothesis (4). All patients were screened for deletions. Seven
cases had no deletions found, with 4 positive muscle biopsy
(absence of dystrophin, Patients #7, #8, #9, and #10) confirming
the diagnosis. We stated that, in only 3 cases (no exon deletions or
biopsy), the diagnosis was based on the classical phenotype and
typical familial history.
We apologize for not having cited the article by Giglio et al. (5),
which has elegantly demonstrated the capability of ultrasonic tissue
characterization in Duchenne patients.
Our conclusions are based solely on CMR’s capability of identify-
ing MF in the myocardium of this small, but sufficient, group of
patients. Our conclusion was that CMR is able to detect MF in
muscular dystrophy patients earlier than routine cardiologic evalua-
tion, not including any widely unavailable sophisticated technology.
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